Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore! Learn More →

← Back to all trials

Recruiting NCT07465653

A Safety and Tolerability Study of HJB647 in Heart Failure Participants With Reduced Ejection Fraction

Conditions: Heart Failure With Reduced Ejection Fraction

Sex: All

Ages: 18 Years – 100 Years

Healthy volunteers: No

Phase: PHASE1

Enrollment: 12

Sponsor: Novartis Pharmaceuticals

Location: Synergy Healthcare Bradenton Florida

Summary

The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of HJB647 at two different doses in participants with chronic stable heart failure with reduced or mildly reduced ejection fraction (HFrEF/HFmrEF).

Eligibility Criteria

Inclusion Criteria: Participants eligible for inclusion in this study must meet all of the following criteria: * Men and women aged 18 years or older * Stable NYHA functional class II-III * LVEF \

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT07465653). StuddyBuddy aggregates publicly available trial information.